Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update

1mon ago, source: Nasdaq

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune and ...

Forte Biosciences, Inc. (FBRX)

6d ago, source: Yahoo Finance

DALLAS, March 18, 2024--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today ...

Forte Bio Board Ordered to Face White Squire, Poison Pill Case

8d ago, source:

Forte Biosciences Inc. directors lost their bid Monday to dodge allegations that they sought to keep their seats by adopting ...

Forte Biosciences Stock (NASDAQ:FBRX), Analyst Ratings, Price Targets, Predictions

16d ago, source: Benzinga.com

Forte Biosciences Inc has a consensus price target of $13.71, established from looking at the 8 latest analyst ratings. The last 3 analyst ratings were released from Ladenburg Thalmann ...

Buy Recommendation for Forte Biosciences on Strong Potential of Novel FB-102 Treatment and Market Position

17d ago, source: Business Insider

Begin your TipRanks Premium journey today. Forte Biosciences (FBRX) Company Description: Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company, which engages in the development ...

Forte Biosciences Inc.

1mon ago, source: CNN

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The firm's lead product includes FB-401, which is a live biotherapeutic ...

Forte Biosciences Inc Ordinary Shares FBRX

7d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Forte Biosciences Inc (FBRX)

29d ago, source: Investing

Forte Biosciences, Inc.(FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced key R&D updates for FB-102 and the closing of financing to support the ...

Forte Biosciences, Inc. (FBRX)

1mon ago, source: Yahoo Finance

DALLAS, March 18, 2024--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced ...